New Lantus guidance released
November 2, 2012
SANOFI has welcomed new
guidance published by the
Australian Diabetes Society (ADS)
on the safety of insulin glargine
(Lantus), which the company says
has finally closed the books on any
link between the drug and cancer.
The new position statement says
“ADS believes that the current data
do not support a relationship
between the use of insulin glargine
and malignancy.”
It adds that patients with diabetes
taking insulin glargine (Lantus) do
not need to change their insulin
therapy, and glargine therapy can
be initiated without concerns that
it will increase the risk of
developing cancer.
In particular ADS says there is no
increase in breast cancer rates, with
Sanofi acting medical director, Dr
Tal Rapke, saying the updated
statment helps bring clarity to
patients and doctors on the
appropriateness of insulin glargine
as a treatment for diabetes.
The ADS announcement follows a
large-scale epidemiological
program conducted by
independent researchers in
northern Europe as well as in
California and the University of
North Carolina in the USA, which
found there was no increased risk
of cancer in people with diabetes
treated with Lantus compared to
those treated with other insulins.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Nov 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Nov 12
